With the prevalence of diabetes expected to increase, you need one global partner to accelerate your diabetes research from discovery to post-market. At Q2
Solutions, we offer a complete range of diabetes drug development solutions including central
and genomic testing
and biomarker services
– plus support for companion diagnostic
studies for personalized medicine.
Our lab experience includes testing services in support of clinical trials for insulins, GLP-1/glucagon dual-agonists, SGLT2 inhibitors, DPP-4 inhibitors (gliptins), combination therapies and more. See our infographic
to learn more about our broad range of testing services and capabilities for diabetes studies.
We also participate in many proficiency and certification programs for endocrine testing, such as:
- The National Glycohemoglobin Standardization Program (NGSP)
- CDC Lipid Standardization Program
- CAP Proficiency Scheme
Our industry renowned scientific experts are here to help you navigate today’s increasingly complex drug development programs. Contact us
today to learn how we can advance your diabetes product development program.